Your browser doesn't support javascript.
loading
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
Meulendijks, Didier; Jacob, Wolfgang; Martinez-Garcia, Maria; Taus, Alvaro; Lolkema, Martijn P; Voest, Emile E; Langenberg, Marlies H G; Fleitas Kanonnikoff, Tania; Cervantes, Andres; De Jonge, Maja J; Sleijfer, Stefan; Soerensen, Morten Mau; Thomas, Marlene; Ceppi, Maurizio; Meneses-Lorente, Georgina; James, Ian; Adessi, Celine; Michielin, Francesca; Abiraj, Keelara; Bossenmaier, Birgit; Schellens, Jan H M; Weisser, Martin; Lassen, Ulrik N.
Afiliación
  • Meulendijks D; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Jacob W; Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany. wolfgang.jacob@roche.com.
  • Martinez-Garcia M; Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
  • Taus A; Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
  • Lolkema MP; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands.
  • Voest EE; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Langenberg MH; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Fleitas Kanonnikoff T; Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain.
  • Cervantes A; Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain.
  • De Jonge MJ; Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands.
  • Sleijfer S; Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands.
  • Soerensen MM; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
  • Thomas M; Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
  • Ceppi M; Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
  • Meneses-Lorente G; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn, United Kingdom.
  • James I; Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
  • Adessi C; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Michielin F; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Abiraj K; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
  • Bossenmaier B; Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
  • Schellens JH; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Weisser M; Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
  • Lassen UN; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
Clin Cancer Res ; 22(4): 877-85, 2016 Feb 15.
Article en En | MEDLINE | ID: mdl-26463709
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Anticuerpos Monoclonales Humanizados / Analgésicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Anticuerpos Monoclonales Humanizados / Analgésicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Países Bajos